×
0.0285714285714286 0.0285714285714286 0.0285714285714286 0.0285714285714286 0.0285714285714286 0.0285714285714286 0.0257142857142857 0.0206142857142858
Stockreport

Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome

Urovant Sciences Ltd (UROV)  More Company Research Source: Business Wire
Last urovant sciences ltd earnings: 2/13 04:05 pm Check Earnings Report
PDF BASEL, Switzerland & IRVINE, Calif.--(BUSINESS WIRE)-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, announced the company enrolled its first patient in a Phase 2a clinical trial evaluating vibegron in patients with abdominal pain due to irritable bowel syndrome (IBS) on December 31, 2018. The company’s investigational new drug application was recently accepted by the U.S. Food and Drug Administration. There are no currently marketed drugs indicated specifically for IBS-associated pain.1 The Phase 2a trial is a double-blind, placebo-controlled study in women with abdominal pain due to IBS with predominant diarrhea (IBS-D) or mixed episodes of diarrhea and constipation (IBS-M). The study is expected to enroll approximately 200 patients in the United States, randomized to receive either 75 mg of vibegron or plac [Read more]

IMPACT SNAPSHOT EVENT TIME: UROV
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
UROV alerts

from News Quantified
Opt-in for
UROV alerts

from News Quantified